2013
Galena Biopharma Provides Product Pipeline Update at the ASCO 2013 Annual Meeting Monday, June 3, 2013
Galena Biopharma to Present at the Jefferies 2013 Global Healthcare Conference Thursday, May 30, 2013
Galena Biopharma to Present at the 2013 Marcum MicroCap Conference Thursday, May 23, 2013
Galena Biopharma Poster Presentation at the American Pain Society 32nd Annual Scientific Meeting Thursday, May 9, 2013
VIDEO RELEASE -- Galena Biopharma Reports First Quarter 2013 Financial Results Thursday, May 9, 2013
William L. Ashton Joins Galena Biopharma's Board of Directors Wednesday, May 1, 2013
Galena Biopharma to Present at the 12th Annual Needham Healthcare Conference Wednesday, April 24, 2013
Galena Biopharma to Present at the 2013 BIO International Convention Tuesday, April 16, 2013
Galena Biopharma to Present at the 20th Annual Future Leaders in the Biotech Industry Conference Friday, March 29, 2013
Galena Biopharma Acquires Abstral(R) (fentanyl) Sublingual Tablets in U.S., a Novel, Best-in-Class Treatment Approved for Breakthrough Cancer Pain Monday, March 18, 2013
Galena Biopharma Receives 2013 Global Frost & Sullivan Award for New Product Innovation for NeuVax(TM) Thursday, March 14, 2013
Galena Biopharma Reports Year-End 2012 Financial Results Tuesday, March 12, 2013
Galena Biopharma to Present at the 25th Annual ROTH Conference Monday, March 11, 2013
Galena Biopharma to Present at the 7th Annual Bio-Europe International Partnering Conference Monday, March 4, 2013
Galena Biopharma to Present at the 15th Annual Bio CEO & Investor Conference Tuesday, February 5, 2013
2012
Galena Biopharma Announces Pricing of Public Offering of Common Stock and Warrants Tuesday, December 18, 2012
Galena Biopharma Announces Public Offering of Common Stock and Warrants Monday, December 17, 2012
Galena Biopharma Presents Final Landmark 60-Month Results From NeuVax(TM) Phase 1/2 Trials at the 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium Friday, December 7, 2012
Galena Biopharma and Leica Biosystems Announce Partnership to Develop Companion Diagnostic for HER2 Screening in Women With Breast Cancer Thursday, December 6, 2012
Galena Biopharma to Present at the Oppenheimer 23rd Annual Healthcare Conference Wednesday, December 5, 2012
Galena Biopharma Announces Signature of Commercialization Partnership With Teva for Israel Tuesday, December 4, 2012
Galena Biopharma Announces NeuVax(TM) Poster Presentations at the 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium Thursday, November 29, 2012
Galena Biopharma to Present at the Piper Jaffray 24th Annual Healthcare Conference Tuesday, November 20, 2012
Galena Biopharma Reports Third Quarter 2012 Financial Results Tuesday, November 13, 2012
Galena Biopharma to Present at the Lazard Capital Markets 9th Annual Healthcare Conference Thursday, November 8, 2012
Galena Biopharma Reports Clinical Biomarker Data Demonstrating the Role of NeuVax(TM) in Preventing Breast Cancer Recurrence Friday, October 26, 2012
Galena Biopharma to Present at the 3rd Annual Cancer Immunotherapy: A Long-Awaited Reality Conference Thursday, September 27, 2012
Galena Biopharma to Present at the 2012 Aegis Capital Healthcare Conference Friday, September 21, 2012
Galena Biopharma to Present at BioX: Noble Financial Capital Markets' Life Sciences Exposition Tuesday, September 18, 2012
Galena Biopharma to Present at the Rodman and Renshaw 14th Annual Investment Conference Tuesday, September 4, 2012
Galena Biopharma to Present at BioCentury's 2012 NewsMakers in the Biotech Industry Conference Tuesday, August 28, 2012
Galena Biopharma to Present at the 2012 Southern California Investor Conference Thursday, August 23, 2012
Galena Biopharma Reports Second Quarter 2012 Financial Results Tuesday, August 14, 2012
Galena Biopharma Issued Folate Binding Protein (FBP) Cancer Vaccine Patent in Japan Monday, August 13, 2012
Galena Biopharma Issued NeuVax(TM) U.S. Patent Wednesday, July 18, 2012
Galena Biopharma to Present at the 2012 BIO International Convention Monday, June 18, 2012
Galena Biopharma to Present at the Marcum Microcap Conference Wednesday, June 13, 2012
Galena Biopharma Announces NeuVax(TM) (E75) Improves Disease-Free Survival at 60-Month Median Follow-Up Tuesday, June 5, 2012
Galena Biopharma Presents NeuVax Phase 1/2 Boosters Improve Disease-Free Survival at 60-Month Median Follow-Up Monday, June 4, 2012
Galena Biopharma Adds Oncology Expert Dr. Gabriel Hortobagyi to Its Scientific Advisory Board Thursday, May 31, 2012
Galena Biopharma Reports First Quarter 2012 Financial Results Monday, May 14, 2012
Galena Biopharma Announces Expansion of Scientific Advisory Board Thursday, May 10, 2012
Galena Biopharma Notified That RXi Pharmaceuticals' Common Stock to Commence Trading Under Ticker Symbol "RXII" Thursday, May 10, 2012
Galena Biopharma to Present at the Immunotherapy Leaders' Forum 2012 Wednesday, May 9, 2012
Galena Biopharma to Present Updated NeuVax(TM) Results at ASCO (American Society of Clinical Oncology) 2012 Annual Meeting Tuesday, May 8, 2012
Galena Biopharma Strengthens Clinical Management Team Thursday, May 3, 2012
Galena Biopharma Expands Folate Binding Protein Vaccine Intellectual Property With Notice of Allowance for U.S. Patent Tuesday, May 1, 2012
Galena Biopharma Takes Final Actions to Complete Spin-Off of RXi Pharmaceuticals Thursday, April 26, 2012
Galena Biopharma Announces Exercise of Underwriters' Over-Allotment Option and Closing of $14.5 Million Public Offering of Common Stock Monday, April 16, 2012
Galena Biopharma to Present at the World Vaccine Trials Congress Tuesday, April 10, 2012
Galena Biopharma Announces Pricing of Public Offering of Common Stock Thursday, April 5, 2012
Galena Biopharma Announces Public Offering of Common Stock Wednesday, April 4, 2012
Galena Biopharma Reports Fourth Quarter and 2011 Financial Results and Provides Business Update Wednesday, March 28, 2012
Galena Biopharma Announces Addition of Renowned Breast Cancer Physician to Its Scientific Advisory Board Wednesday, March 21, 2012
Galena Biopharma Strengthens NeuVax(TM) Intellectual Property Position With Notice of Allowance for U.S. Patent Tuesday, March 20, 2012
Galena Biopharma to Present at the 24th Annual ROTH Conference Wednesday, March 7, 2012
Galena Biopharma Announces Expansion of Scientific Advisory Board Wednesday, February 29, 2012
Galena Biopharma to Present at the Cancer Targets and Therapeutics Conference Tuesday, February 28, 2012
Galena Biopharma Establishes Record Date for Spin-Off Stock Dividend of RXi Pharmaceuticals Shares Monday, February 27, 2012
Galena Biopharma to Present at the Cancer Immunotherapy Summit Thursday, February 23, 2012
Galena Biopharma to Present at the 2nd Annual Emerging Targeted Oncology Partnering Forum Friday, February 17, 2012
Galena Biopharma Initiates Enrollment in Phase 1/2 Trial for Folate Binding Protein (E39) Targeted Peptide Vaccine in Ovarian and Endometrial Cancer Patients Tuesday, February 14, 2012
Galena Biopharma Announces Launch of New Patient Website: NeuVax.com Thursday, February 9, 2012
Galena Biopharma to Present at the 14th Annual BIO CEO & Investor Conference Tuesday, February 7, 2012
Galena Biopharma to Present at The Immunotherapeutics Partnering and Dealmaking Conference Monday, January 30, 2012
Galena Biopharma to Present at the World Cancer Immunotherapy Conference Tuesday, January 24, 2012
Galena Biopharma Initiates Patient Enrollment in NeuVax(TM) Phase 3 PRESENT Trial to Prevent Breast Cancer Recurrence Friday, January 20, 2012
Galena Biopharma Announces Investigational New Drug Approval for Phase 2 Trial for NeuVax(TM) (E75 + GM-CSF) Combined With Herceptin(R) (trastuzumab) Thursday, January 5, 2012
Galena Biopharma to Present at the Biotech Showcase 2012 Conference Thursday, January 5, 2012
2011
Galena Biopharma Presents Phase 2 Trial Design for NeuVax(TM) (E75 + GM-CSF) Combined With Herceptin(R) (Trastuzumab) at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium Friday, December 9, 2011
Galena Biopharma Presents 5 Year NeuVax(TM) Efficacy Data at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium Wednesday, December 7, 2011
Galena Biopharma Enters Into Exchange Agreements With Warrant Holders Tuesday, December 6, 2011
Galena Biopharma to Present at the NYSSA 15th Annual Biotech and Specialty Pharmaceuticals Conference Monday, November 28, 2011
Galena Biopharma Announces NeuVax(TM) Poster Presentations at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium Friday, November 18, 2011
Galena Biopharma Reports Third Quarter 2011 Financial Results and Provides Business Update Monday, November 14, 2011
Galena Biopharma to Present at the Lazard Capital Markets 8th Annual Healthcare Conference Tuesday, November 8, 2011
Galena Biopharma Presents Positive NeuVax(TM) Clinical Results at the 26th Annual Meeting of the Society for Immunotherapy of Cancer Friday, November 4, 2011
Galena Biopharma to Present Updated NeuVax(TM) Clinical Results at the 26th Annual Meeting of the Society for the Immunotherapy of Cancer Wednesday, October 26, 2011
Galena Biopharma Accelerates Strategy to Focus on Late Stage Targeted Cancer Drug Development Tuesday, October 25, 2011
Galena Biopharma to Present at the 10th Annual Biotechnology Investor Forum Friday, October 21, 2011
Galena Biopharma's NeuVax (E75) Clinical Trial Results Published in Cancer Thursday, October 20, 2011
Galena Biopharma to Present at the 2nd Annual Cancer Immunotherapy: A Long-Awaited Reality Conference Wednesday, October 5, 2011
Galena Biopharma Hires Hana B. Moran as Vice President, Regulatory Affairs and Compliance Tuesday, October 4, 2011
RXi Pharmaceuticals(R) to Strengthen Strategic Focus by Separating Into Two Publicly Traded Companies Monday, September 26, 2011
RXi Pharmaceuticals Licenses Novel, Targeted Cancer Vaccine for Gynecological Cancers Wednesday, September 21, 2011
RXi Pharmaceuticals Provides Positive NeuVax(TM) Phase 3 Clinical Trial Update Monday, September 12, 2011
RXi Pharmaceuticals to Present at the 13th Annual Rodman & Renshaw Healthcare Conference Thursday, September 8, 2011
RXi Pharmaceuticals Presents RNAi Data at the 7th Annual Meeting of the Oligonucleotide Therapeutics Society Wednesday, September 7, 2011
RXi Pharmaceuticals Provides Update and Reports Financial Results for Q2 2011 Monday, August 15, 2011
RXi Pharmaceuticals Strengthens NeuVax™ (E75) Patent Portfolio Wednesday, July 13, 2011
RXi Pharmaceuticals to Present at BIO International Convention Friday, June 24, 2011
RXi Pharmaceuticals Presents Additional Positive Phase 2 Efficacy Results for Combination of NeuVax™ (E75) and Trastuzumab in Breast Cancer at ASCO Wednesday, June 8, 2011
RXi Pharmaceuticals Announces Positive NeuVax™ (E75) Phase 2 Efficacy Results after 36 Months of Follow-Up Monday, June 6, 2011
RXi Pharmaceuticals Presents Updated NeuVax™ (E75) Data At ASCO Thursday, May 19, 2011
RXi Pharmaceuticals Reports Financial Results for the First Quarter of 2011 Tuesday, May 17, 2011
RXi Pharmaceuticals and the University of Massachusetts Medical School Announce Massachusetts Life Sciences Center Cooperative Research Grant for RNAi Therapeutics for ALS Thursday, April 28, 2011
RXi Pharmaceuticals Awarded $580,000 in NIH Grants to Advance RNAi Therapeutics Tuesday, April 26, 2011
RXi Pharmaceuticals Prices $12 Million Public Offering of Common Stock and Warrants Friday, April 15, 2011
RXi Pharmaceuticals Announces Public Offering of Common Stock and Warrants Thursday, April 14, 2011
RXi Pharmaceuticals Completes Apthera Acquisition Thursday, April 14, 2011
RXi Pharmaceuticals to Webcast Presentation at BioCentury Future Leaders in the Biotech Industry Conference Thursday, April 7, 2011
RXi Pharmaceuticals Aggressively Moves into Late-Stage Clinical Development with the Agreement to Acquire Apthera, Inc. Thursday, March 31, 2011
RXi Pharmaceuticals Announces $16.2 Million Registered Direct Financing Wednesday, March 23, 2011
RXi Pharmaceuticals Presents New Preclinical RNAi Data at the Keystone Mechanism and Biology of Silencing Conference Monday, March 21, 2011
RXi Pharmaceuticals Prices $8.1 Million Public Offering of Common Stock and Warrants Tuesday, March 1, 2011
RXi Pharmaceuticals Announces Public Offering of Common Stock and Warrants Monday, February 28, 2011
RXi Pharmaceuticals to Webcast Presentation at the 13th Annual BIO CEO & Investor Conference Tuesday, February 8, 2011
RXi Pharmaceuticals Initiates Development Program for Dermal Anti-Scarring Product Candidate Thursday, February 3, 2011
RXi Pharmaceuticals Announces Positive Initial Results in microRNA Therapeutics Thursday, January 27, 2011
Generex and RXi Pharmaceuticals Announce Positive Research Data Using RNAi Technology in the Development of Therapeutic Vaccines for Cancer Thursday, January 6, 2011
RXi Pharmaceuticals to Webcast Presentation at the Biotech Showcase Conference Tuesday, January 4, 2011
2010
RXi Pharmaceuticals Nominates Dermal Anti-Scarring RNAi Product Candidate to Advance into Development Friday, December 17, 2010
RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2010 Monday, November 15, 2010
RXi Pharmaceuticals to Webcast Presentation at the Lazard Capital Markets Annual Healthcare Conference Wednesday, November 10, 2010
RXi Pharmaceuticals Awarded $1 Million in IRS Grants to Advance RNAi Therapeutics Tuesday, November 2, 2010
RXi Pharmaceuticals to Webcast Presentation at the 9th Annual BIO Investor Forum Thursday, September 30, 2010
RXi Pharmaceuticals and EyeGate Pharma Announce Collaboration Focused on Non-Invasive Ocular Delivery of RNAi Therapeutics Wednesday, September 22, 2010
RXi Pharmaceuticals to Webcast Presentation at the Rodman & Renshaw Global Investment Conference Tuesday, September 7, 2010
RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2010 Wednesday, August 11, 2010
RXi Pharmaceuticals to Host Second Quarter 2010 Conference Call on Wednesday, August 11, 2010 Thursday, August 5, 2010
RXi Pharmaceuticals Awarded NIH Grant to Advance RNAi Therapeutics Tuesday, July 13, 2010
RXi Pharmaceuticals Announces New Focused Therapeutic Strategy for its Next Generation RNAi Technology Thursday, June 10, 2010
Philips and RXi Pharmaceuticals Sign Agreement to Jointly Research Innovative Image-Guided Therapy Concepts Based on RNAi Thursday, June 3, 2010
RXi Pharmaceuticals CEO to Present at the Jefferies 2010 Global Life Sciences Conference Wednesday, June 2, 2010
RXi Pharmaceuticals Reports Financial Results for the First Quarter of 2010 Monday, May 17, 2010
RXi Pharmaceuticals CEO to Present at the Rodman & Renshaw Annual Global Healthcare Conference Tuesday, May 11, 2010
RXi Demonstrates Robust in vivo Uptake and Significant Silencing Using its Self-Delivering rxRNA(TM) Compounds Administered to Mouse Retinal Cells Tuesday, May 4, 2010
RXi Pharmaceuticals to Deliver Presentations at Upcoming Conferences Outlining the Development and Progression of its Next Generation rxRNA(TM) Therapeutic Platform Friday, April 23, 2010
RXi Pharmaceuticals Presents at AACR Conference, Highlighting the Potential for RNAi Therapeutics in Oncology Monday, April 19, 2010
RXi Pharmaceuticals Announces Formation of microRNA Research Collaboration with Mirna Therapeutics Monday, April 12, 2010
RXi Pharmaceuticals and TransDerm Announce Formation of Research Collaboration Tuesday, April 6, 2010
RXi Pharmaceuticals CEO to Present at the Future Leaders in the Biotech Industry Investment Conference Thursday, April 1, 2010
RXi Pharmaceuticals Reports Fourth Quarter and 2009 Financial Results Wednesday, March 31, 2010
RXi Pharmaceuticals to Host Year-End 2009 Earnings Conference Call and Webcast on Wednesday, March 31, 2010 Monday, March 29, 2010
RXi Pharmaceuticals to Present New Preclinical Data Demonstrating the Robust Performance of its RNAi Therapeutics Platform Thursday, March 25, 2010
RXi Pharmaceuticals to Webcast Presentation at the ROTH 22nd Annual OC Growth Stock Conference Tuesday, March 9, 2010
RXi Pharmaceuticals to Webcast Presentation at the 12th Annual BIO CEO & Investor Conference Monday, February 1, 2010
RXi Pharmaceuticals Presented New Pre-Clinical Data at the Keystone RNAi Silencing Conference Tuesday, January 19, 2010
RXi Pharmaceuticals and the University of Massachusetts Medical School Announce Research Collaboration Focused on Ocular Disease Thursday, January 14, 2010
RXi Pharmaceuticals to Webcast Presentation at the Biotech Showcase Conference Thursday, January 7, 2010